MGIA
JAZZ icon

Moneta Group Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Moneta Group Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,611
Closed -$200K – 718
2025
Q1 		$200K Buy
+1,611
New +$210K ﹤0.01% 638

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Moneta Group Investment Advisors's JAZZ Position: Q2 2025 in Review

Moneta Group Investment Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 1,611 shares — an estimated $200K sold.

Moneta Group Investment Advisors first reported a position in JAZZ in Q1 2025 and held it in 1 quarter. The position peaked at $200K in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Moneta Group Investment Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Moneta Group Investment Advisors sold 1,611 Jazz Pharmaceuticals shares in Q2 2025, an estimated $200K.
  • Moneta Group Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Moneta Group Investment Advisors's Jazz Pharmaceuticals position peaked at $200K in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Moneta Group Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.